ABSTRACT
Acute myocardial infarction (AMI) is associated with systemic inflammatory processes and metabolic alterations. Microbial-derived metabolites, such as short-chain fatty acids and trimethylamine N-oxide (TMAO), have emerged in recent years as key players in the modulation of inflammation, with potential implications for cardiovascular diseases. We performed a prospective observational study that monitored the serological concentration of bacterial metabolites in 45 young patients (<55 years) without cardiovascular risk factors but with AMI, at hospital admission and at 3 months of follow-up, and compared them with a control group. TMAO and acetate levels were significantly higher in AMI, whereas butyrate and propionate were significantly lower. The acetate/propionate ratio showed the most discrimination between AMI and controls by receiver operating characteristic analysis (area under the curve 0.769, P < 0.0001). A multivariate logistic regression model revealed that this ratio was independently associated with AMI. Short-chain fatty acid concentrations, but not TMAO, exhibited significant correlations with inflammatory and coagulation parameters. Three months after the acute AMI event, all metabolite levels returned to those observed in healthy controls except butyrate. In conclusion, our study reveals disturbances of the serological concentration of microbiota-derived metabolites in AMI that are also related to inflammatory and coagulation parameters. These findings highlight an interesting field of study in the potential role of microbial metabolites from gut in cardiovascular disease.
ABSTRACT
No disponible
Subject(s)
Humans , Female , Child , Meningitis, Listeria/complications , Meningitis, Listeria/diagnosis , Meningitis, Listeria/drug therapy , Listeria monocytogenes , Listeria monocytogenes/isolation & purification , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/diagnosis , Antibodies, Monoclonal/therapeutic use , Nephritis/complications , Hydroxychloroquine/therapeutic use , Cyclophosphamide/therapeutic use , Bacteremia/complications , Methylprednisolone/therapeutic use , Leukocytosis/complicationsSubject(s)
Immunocompromised Host , Immunosuppressive Agents/adverse effects , Listeriosis/immunology , Lupus Erythematosus, Systemic/drug therapy , Meningoencephalitis/immunology , Mycophenolic Acid/adverse effects , Rituximab/adverse effects , Child , Drug Therapy, Combination , Female , Humans , Immunosuppressive Agents/therapeutic use , Listeriosis/diagnosis , Lupus Erythematosus, Systemic/immunology , Meningoencephalitis/diagnosis , Mycophenolic Acid/therapeutic use , Rituximab/therapeutic useABSTRACT
Arthritis associated with Behçet's disease is typically nonerosive and nondeforming, and most patients respond to colchicine treatment. However, destructive arthritis and refractory arthritis have also been reported on occasion. Elevated white blood cell counts may occur in synovial fluid in BD, but pseudoseptic arthritis is a very rare event in this disease. We report a patient with BD and rapidly progressive deforming pseudoseptic arthritis refractory to colchicine, corticosteroids, and methotrexate, who entered remission after infliximab treatment.
